When Ortho Clinical Diagnostics lived under the roof of Johnson & Johnson, it had the luxury of focusing on its product and service mix — and not a whole lot else.
Clinical
Five things for pharma marketers to know: Friday, December 8, 2017
FDA approves first nebulized LAMA COPD treatment; more than 2,000 cancer immunotherapies in development; FDA issues 3D-printing guidance
Five things for pharma marketers to know: Thursday, November 16, 2017
Docs biased against research from poor countries, study finds; Astellas probed over patient-assistance charity support; Acorda reports deaths in Parkinson’s trial
Five things for pharma marketers to know: Monday, November 13, 2017
Dynavax receives FDA approval for hepatitis-B vaccine; Novartis strikes R&D deal with gene-editing startup; White House nominates new HHS head
Can marketing techniques save clinical trials?
No crucial area in pharma is more desperately in need of a fix — or more stubbornly resistant to change.
Five things for pharma marketers to know: Monday, July 31, 2017
FDA launches digital health pre-certification pilot; J&J’s experimental RA drug raises safety concerns; AstraZeneca gets breakthrough status for Imfinzi
Five things for pharma marketers to know: Thursday, July 6, 2017
The FDA suspends three Keytruda studies; drug and device makers gave $8 billion in payments to providers in 2016; Opdivo beat Yervoy in skin-cancer trial
Five things for pharma marketers to know: Monday, April 10, 2017
Gilead receives approval to market Harvoni, Sovaldi to adolescents; OncoMed ends mid-stage trials for pancreatic cancer drug; researchers use facial recognition software to diagnose
Five things for pharma marketers to know: Monday, March 20, 2017
Study finds SGLT-2 inhibitors lowered risk of death; former FDA commissioners raise drug importation issues; Bayer, J&J’s Xarelto lowered VTE risk in study
